Aquestive Therapeutics Inc. (AQST), which listed its IPO on the Nasdaq Global Market as recently as July 25, is gearing up for another major event.The Company’s investigational product Sympazan (AQST-120) for the treatment of seizures associated with Lennox-Gastaut Syndrome is under FDA review, with a decision expected on August 31, 2018.Sympazan is an oral soluble film formulation of clobazam, a benzodiazepine used as an adjunctive therapy for seizures associated with Lennox-Gastaut Syndrome.Clobazam, marketed under brand name Onfi in the United States, is currently available in either tablet form or liquid suspension. If approved, the Company anticipates launching Sympazan by the end of 2018.AQST closed Wednesday’s (Jul 25) trading at $16.05, up 7.00%.